Advanced Accelerator Applications,
|Advanced Accelerator Applications, S.A. (AAA), a Novartis company, is an innovative medicines company developing targeted radioligand therapies and precision imaging radioligands for oncology indications. We are committed to transforming patients’ lives by leading innovation in nuclear medicine.
Founded in 2002, AAA has a legacy as a pioneer in the development and delivery of radiopharmaceutical drugs for diagnostic imaging. More recently, AAA has focused its efforts on developing targeted radioligand therapies and precision imaging diagnostics that target specific markers that are over-expressed by certain types of solid tumors. AAA currently employs more than 1,100 associates across 31 sites in 12 countries; with 19 manufacturing facilities in 8 countries and 6 research and development sites.
AAA-NP-GL-0446-22 AI2211229085 12/22
|Spectrum Dynamics is spearheading the transformation of SPECT imaging scanners from analog to digital detection technology, enabling hospitals and clinicians to provide superior healthcare services with improved image quality, efficiency, and advanced clinical applications.
Spectrum launched the world’s first digital cardiac SPECT system: the D-SPECT®, in 2007. The D-SPECT employs Broadview Technology: swiveling digital detectors made of Cadmium Zinc Telluride (CZT) and ingenious hardware design and unique 3D algorithms for state-of-the-art imaging. It features TruCorr: 1st Artificial Intelligence (IA) based software to generate attenuation corrected myocardial perfusion images using emission-only data.
Spectrum’s latest innovation is the VERITON-CT® SPECT/CT: featuring a 360° CZT detector design with a full diagnostic, high-resolution CT; the industry’s most advanced hybrid nuclear camera. The VERITON-CT 400 Series can image the range of commonly used radionuclides in Nuclear Medicine: low, medium, and high-energy isotopes. The scanner design and advanced algorithms enable routine 3D total body NM/CT imaging, with a choice of 16-slice or 64-slice CT. Its post-processing tools allow for advanced quantitative analysis of 3D data. Plus, unique TruFlow capability: 4D SPECT/CT for dynamic flow applications.
|Blue Earth Diagnostics
||Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is an international molecular imaging company on a growth trajectory to develop and commercialise innovative, well-differentiated diagnostic solutions that inform patient care and drive future therapies in cancer. Formed in 2014, the Company’s success is driven by its management expertise, supported by a proven track record of rapid development and commercialisation of positron emission tomography radiopharmaceuticals. With a clinical focus in cancer, Blue Earth Diagnostics’ expanding pipeline encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialisation of precision radiopharmaceuticals for potential use in diagnostic imaging and therapy. For more information, please visit: www.blueearthdiagnostics.com.
PP-EU-0042 / July 2021
|ITM Isotope Technologies
|ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.
||At Siemens Healthineers, our purpose is to drive innovation to help humans live healthier and
longer. Through our products, services and solutions we help physicians, medical staff, and
healthcare providers prevent illnesses from occurring and to correctly diagnose and determine the
right treatments for people who do become ill – resulting in fewer complications, shorter hospital
stays, and faster patient recovery.
Our mission is to enable healthcare providers to increase value by expanding precision medicine,
transforming care delivery, improving the patient experience, and digitalizing healthcare. With our
comprehensive portfolio – from in-vitro diagnostics and imaging to therapy and follow-up care – we
address the complete care continuum for many of the world’s most threatening diseases.
Every hour, more than 240,000 patients are touched by technologies provided by Siemens
Healthineers. We are at the center of clinical decision making with almost three-quarters of all
critical clinical decisions influenced by our solutions. We are a leading medical technology company
with over 120 years of experience and more than 65,000 highly dedicated employees around the
globe who are innovating every day, truly shaping the future of healthcare.
||Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic (‘theranostic’) radiopharmaceuticals.
Using targeted radiation to combine imaging and therapy, Telix’s technology has the potential to change the way clinicians are able to find and treat cancer and rare diseases, to better inform treatment decisions and deliver truly personalised therapy.
Telix’s broad research pipeline aims to address significant unmet medical need in prostate, kidney, brain (glioblastoma), and hematologic cancers as well as a range of immunologic and rare diseases. Telix’s product development strategy is to closely integrate with, and add value to, standard of care, reflective of the modern team-based approach to managing cancer and rare diseases.
This pipeline is underpinned by a reliable and secure global supply chain, manufacturing and distribution network. The company’s manufacturing hub in Belgium will deliver significant operational flexibility, R&D capabilities, and support commercial production requirements in Europe.
Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent and has more than 20 clinical trials underway worldwide (including partnered investigator-led studies).
Headquartered in Melbourne, Australia, Telix has international commercial operations in Europe (Belgium and Switzerland), Japan, and the United States.